![](/img/cover-not-exists.png)
CAT-1004, an oral agent targeting NF-κB in development for treatment of Duchenne muscular dystrophy: Phase 1/2 study design
Donovan, J., Sweeney, H., Vandenborne, K., Russman, B., Jirousek, M., Finkel, R.Volume:
25
Language:
english
Journal:
Neuromuscular Disorders
DOI:
10.1016/j.nmd.2015.06.278
Date:
October, 2015
File:
PDF, 205 KB
english, 2015